{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:24:50Z","timestamp":1790760290429,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of berzosertib plus cisplatin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients with advanced solid tumours refractory or resistant to standard of care therapies received ascending doses of cisplatin (day 1) and berzosertib (days 2 and 9) every 3 weeks (Q3W).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-one patients received berzosertib (90\u2013210\u2009mg\/m<jats:sup>2<\/jats:sup>) and cisplatin (40\u201375\u2009mg\/m<jats:sup>2<\/jats:sup>) across seven dose levels. The most common grade \u22653 treatment-emergent adverse events were neutropenia (20.0%) and anaemia (16.7%). There were two dose-limiting toxicities: a grade 3 hypersensitivity reaction and a grade 3 increase in alanine aminotransferase. Berzosertib 140\u2009mg\/m<jats:sup>2<\/jats:sup>(days 2 and 9) and cisplatin 75\u2009mg\/m<jats:sup>2<\/jats:sup>(day 1) Q3W was determined as the recommended Phase 2 dose. Cisplatin had no apparent effect on berzosertib pharmacokinetics. Of the 31 patients, four achieved a partial response (two confirmed and two unconfirmed) despite having previously experienced disease progression following platinum-based chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Berzosertib plus cisplatin is well tolerated and shows preliminary clinical activity in patients with advanced solid tumours, warranting further evaluation in a Phase 2 setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trials Identifier<\/jats:title><jats:p>NCT02157792.<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41416-021-01406-w","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T17:53:27Z","timestamp":1622656407000},"page":"520-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours"],"prefix":"10.1038","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Devoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-5609","authenticated-orcid":false,"given":"Simon","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart S.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Diaz-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1406_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik, C. A. & Dolan, M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9\u201323 (2007).","journal-title":"Cancer Treat. Rev."},{"key":"1406_CR2","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N. et al. Drug resistance in cancer: an overview. Cancers 6, 1769\u20131792 (2014).","journal-title":"Cancers"},{"key":"1406_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"1406_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat. Cell Biol. 16, 2\u20139 (2014).","journal-title":"Nat. Cell Biol."},{"key":"1406_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40661-017-0050-0","volume":"4","author":"TJ Herzog","year":"2017","unstructured":"Herzog, T. J. & Monk, B. J. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? Gynecol. Oncol. Res Pract. 4, 13 (2017).","journal-title":"Gynecol. Oncol. Res Pract."},{"key":"1406_CR6","doi-asserted-by":"publisher","first-page":"8311","DOI":"10.1093\/nar\/gky625","volume":"46","author":"D Kim","year":"2018","unstructured":"Kim, D., Liu, Y., Oberly, S., Freire, R. & Smolka, M. B. ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells. Nucleic Acids Res. 46, 8311\u20138325 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1406_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner, A. M., Siemeister, G., L\u00fccking, U., Lefranc, J., Wortmann, L., Lienau, P. et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Mol. Cancer Ther. 19, 26\u201338 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"1406_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ijc.30373","volume":"140","author":"HJ Kim","year":"2017","unstructured":"Kim, H. J., Min, A., Im, S. A., Jang, H., Lee, K. H., Lau, A. et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int. J. Cancer 140, 109\u2013119 (2017).","journal-title":"Int. J. Cancer"},{"key":"1406_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J. D., Maccormick, S., Charlton, P. A. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428\u2013430 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"1406_CR10","doi-asserted-by":"publisher","first-page":"44289","DOI":"10.18632\/oncotarget.6247","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O\u2019Connor, M. J. & Bakkenist, C. J. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 6, 44289\u201344305 (2015).","journal-title":"Oncotarget"},{"key":"1406_CR11","doi-asserted-by":"publisher","first-page":"175883591878665","DOI":"10.1177\/1758835918786658","volume":"10","author":"A Minchom","year":"2018","unstructured":"Minchom, A., Aversa, C. & Lopez, J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther. Adv. Med. Oncol. 10, 1758835918786658 (2018).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1406_CR12","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","volume":"5","author":"AB Hall","year":"2014","unstructured":"Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y. et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 5, 5674\u20135685 (2014).","journal-title":"Oncotarget"},{"key":"1406_CR13","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1538-7445.AM2016-3717","volume":"76","author":"J Pollard","year":"2016","unstructured":"Pollard, J., Reaper, P., Peek, A., Hughes, S., Gladwell, S., Jones, J. et al. Defining optimal dose schedules for ATR inhibitors in combination with DNA damaging drugs: informing clinical studies of VX-970, the first-inclass ATR inhibitor. Cancer Res. 76, 3717 (2016).","journal-title":"Cancer Res."},{"key":"1406_CR14","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1200\/JCO.2016.34.15_suppl.2513","volume":"34","author":"ER Plummer","year":"2016","unstructured":"Plummer, E. R., Dean, E. J., Evans, T. R. J., Greystoke, A., Herbschleb, K., Ranson, M. et al. Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792). J. Clin. Oncol. 34, 2513\u20132513 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1406_CR15","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap, T. A., O\u2019Carrigan, B., Penney, M. S., Lim, J. S., Brown, J. S., de Miguel Luken, M. J. et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 38, 3195\u20133204 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1406_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1406_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctarc.2018.04.001","volume":"16","author":"YD Saito","year":"2018","unstructured":"Saito, Y. D., Li, Z., Lustberg, M., Grenade, C. & Wesolowski, R. Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma. Cancer Treat. Res. Commun. 16, 9\u201312 (2018).","journal-title":"Cancer Treat. Res. Commun."},{"key":"1406_CR18","doi-asserted-by":"publisher","unstructured":"Kurmasheva, R. T., Kurmashev, D., Reynolds, C. P., Kang, M., Wu, J., Houghton, P. J. et al. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65, https:\/\/doi.org\/10.1002\/pbc.26825 (2018).","DOI":"10.1002\/pbc.26825"},{"key":"1406_CR19","unstructured":"FDA U. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. https:\/\/www.fda.gov\/media\/72309\/download (2005)."},{"key":"1406_CR20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41416-018-0286-4","volume":"119","author":"GN Jones","year":"2018","unstructured":"Jones, G. N., Rooney, C., Griffin, N., Roudier, M., Young, L. A., Garcia-Trinidad, A. et al. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. Br. J. Cancer 119, 1233\u20131243 (2018).","journal-title":"Br. J. Cancer"},{"key":"1406_CR21","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-10-0523","volume":"16","author":"CE Redon","year":"2010","unstructured":"Redon, C. E., Nakamura, A. J., Zhang, Y. W., Ji, J. J., Bonner, W. M., Kinders, R. J. et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 16, 4532\u20134542 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1406_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski, S. A., Comaills, V., Buisson, R., Genois, M. M., Nguyen, H. D., Ho, C. K. et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 31, 318\u2013332 (2017).","journal-title":"Genes Dev."},{"key":"1406_CR23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","volume":"36","author":"A Thomas","year":"2018","unstructured":"Thomas, A., Redon, C. E., Sciuto, L., Padiernos, E., Ji, J., Lee, M. J. et al. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J. Clin. Oncol. 36, 1594\u20131602 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1406_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","volume":"39","author":"A Thomas","year":"2021","unstructured":"Thomas, A., Takahashi, N., Rajapakse, V. N, Zhang, X., Sun, Y., Ceribelli, M. et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell 39, 566\u2013579.e7 (2021).","journal-title":"Cancer Cell"},{"key":"1406_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A., Cheng, S.-C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A. et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol.\u00a021, 957\u2013968 (2020).","journal-title":"Lancet Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01406-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01406-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01406-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T13:13:56Z","timestamp":1672319636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01406-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8,17]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01406-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the ethical principles of the International Council for Harmonization guideline for Good Clinical Practice and the Declaration of Helsinki, and with applicable local regulations. All patients provided written informed consent before any study procedures were performed. The study sites received ethical approval from the following institutional review boards\/independent ethical committees: NRES Committee North East\u2014Sunderland, London\u2014Surrey Borders Research Ethics Committee, Institutional Review Board\/Dana Farber Cancer Institute, Western Institutional Review Board, and Biomedical Research Alliance of New York, LLC\/Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to the Merck KGaA, Darmstadt, Germany Data Sharing Policy. All requests should be submitted in writing to the Merck KGaA, Darmstadt, Germany data-sharing portal (). When Merck KGaA, Darmstadt, Germany has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out-licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, Merck KGaA, Darmstadt, Germany will endeavour to gain agreement to share data in response to requests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"G.I.S. has received research funding from Eli Lilly, Merck KGaA\/EMD Serono, Merck & Co., Inc., and Sierra Oncology; and honoraria for serving on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA\/EMD Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Boehringer Ingelheim, ImmunoMet, Artios, and Asana. R.W. has received research funding from Acerta Pharma and AstraZeneca; served on advisory boards for Puma Biotechnology, Pfizer; and served on speakers\u2019 bureau for Roche Diagnostics. C.D. reports honoraria for serving on advisory boards on behalf of Pfizer. S.L. reports personal fees from Eisai, Shionogi, and Prosigna, and was previously employed by Pfizer. J.P. was an employee of Vertex Pharmaceuticals Europe Ltd, Abingdon, UK, at the time of manuscript preparation; and holds stock in Vertex Pharmaceuticals Inc. Current address: Bayer plc, Reading, UK. B.S.H. was an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, at the time of manuscript preparation. Current address: Novartis Institutes for BioMedical Research, Cambridge, MA, USA. M.F. was an employee of Merck KGaA, Darmstadt, Germany, at the time of manuscript preparation. Current address: CureVac, T\u00fcbingen, Germany. I.D.-P. was an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, at the time of manuscript preparation. Current address: GlaxoSmithKline, Zug, Switzerland. R.P. reports honoraria for serving on advisory boards on behalf of Vertex and Merck KGaA relating to this compound; reimbursement for her institution for clinical trials costs; consultancy services to Pierre Faber, Bayer, Octimet, Clovis Oncology, Novartis, Karus Therapeutics, Biosceptre, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics, and Sanofi Aventis; and research funding from AstraZeneca. T.A.Y. is employed as a Medical Director of the Institute for Applied Cancer Science, which has a commercial interest in DDR and other inhibitors; has received research support from AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius\/Formation Biologics, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Sanofi, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals; and has provided consultancy services for Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Kyn Therapeutics, Merck, Pfizer, Roche, Seattle Genetics, and Zai Labs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Financial support for this study was provided by Merck KGaA, Darmstadt, Germany and Vertex Pharmaceuticals Inc., Boston, MA, USA. Medical writing assistance was provided by David Lester of Bioscript Stirling Ltd, Macclesfield, UK, and funded by Merck KGaA, Darmstadt, Germany.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}